Potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs), activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD3100

Second generation papaverine analog, acting as an anticholinergic agent

Selective FXR antagonist, ameliorates glucose homeostasis in type 2 diabetic mice

Polyketide antibiotic, acting as a AKT selective kinase inhibitor, alkylating a regulatory loop cysteine

Progestational hormone, for the treatment of menstrual irregularities, prostatic hypertrophy, and endometrial carcinoma

Potent sPLA2 inhibitor, having no effect on arachidonic acid release and platelet activating factor synthesis

Inducer of Megakaryocyte Differentiation in Erythroleukemia Cells, Impairing Bcr-Abl Signaling Cascades

Natural dual inhibitor of COX-2 and EGFR, improving program death 1 (PD-1) checkpoint blockade therapy through normalizing tumor vasculature and PD-L1 downregulation

Prodrug of melarsen oxide (Mel Ox), irreversibly binding to vicinal sulfhydryl groups on pyruvate kinase, disrupting energy production in the parasite

Inhibitor of cholesterol esterification

Novel Multi-Kinase Inhibitor, Triggering Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition

Potent, selective and orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4)

5-HT2A/D2 receptor antagonist

Novel potent and selective nonpeptide kinin B2 receptor antagonist

Novel Cell Death-Inducing Kinase Inhibitor with Enhanced Selectivity for Cyclin-Dependent Kinases; Antimalarial

Potent cell-permeable, ATP site-targeting inhibitor of CDKs

Potent cell-permeable, ATP site-targeting inhibitor of CDKs

Apoptosis inducer, triggering ROS dependent autophagy-associated apoptosis in a variety of human cancer cell lines and against mutant KRAS expressing cancer cells involving AKT-dependent ROS production

LXR-α antagonist, inhibiting hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells

Anabolic and androgenic agent

Novel selective and potent full KOP receptor agonist with fewer side effects (e.g., sedation or anhedonia) than classic KOP receptor

Novel selective GPR120 agonist